Oral AMXT 1501 Dicaprate in Combination With IV DFMO

INCLUSION CRITERIA * IMPORTANT NOTE- Younger 12-17 year old patients are also eligible for this study if they meet the noted DIPG or DMG criteria noted below, which is separate from Patient Diagnosed with Advanced Solid Tumors. * Patients will be eligible for study participation only if they meet ALL the inclusion criteria applicable to their diagnosis. INCLUSION FOR PATIENTS DIAGNOSED WITH ADVANCED SOLID TUMORS * Understand and sign written IRB-approved informed consent form and be willing to comply with all study procedures. * Diagnosed with unresectable, locally advanced, or metastatic solid tumor for which no standard therapy is recognized or for which standard therapy has failed. Planned tumor types for evaluation include: * Platinum resistant ovarian cancer (including - primary peritoneal cancer and fallopian tube cancer) * Breast cancer * Papillary thyroid cancer * Head and neck cancer * Gastric cancer * Non-small cell lung cancer (NSCLC) * Mesothelioma: Pleural and peritoneal * Esophageal * Endometrial cancer * Cervical * Melanoma * Colorectal cancers (colon, rectal) * Grade 4 Gliomas (including both IDH WT and IDH-mutant astrocytoma) * Must be ≥18 years of age. * Histologically or cytologically documented disease. * Has evaluable or measurable disease by RECIST v1.1 or mRECIST criteria. o For patients with Grade 4 glioma, has evaluable or measurable disease by RANO (Appendix 5). * Provide tumor tissue from biopsy taken during Screenin…